Diagnostic Products Corporation Schedules Conference Call to Discuss Second Quarter 2005 Results

Diagnostic Products Corporation (NYSE:DP) announced
today that it has scheduled a conference call to discuss the Company's
financial results of its second quarter 2005 on Monday, July 25, 2005,
at 9 a.m. Eastern standard time (6 a.m. PST).
   The Company plans to release its financial results before the
market opens on Friday.
   If you are interested in participating in the call, please call
800-260-6066 on the day of the conference, at least ten minutes prior
to the conference in order for the operator to tie you into the call.
The operator will ask you to identify the call with the company name
Diagnostic Products-Jim Brill.
   An "instant replay" of the call will be available until August 4.
If you would like to take advantage of this special service, you can
access it via 800-839-6713 and the code: "7241305." It usually takes
two hours following the conference to set up the recording.

   About Diagnostic Products Corporation

   Diagnostic Products Corporation, founded in 1971, is the global
leader dedicated exclusively to immunodiagnostics. DPC's product menu
includes over 75 immunoassays and more than 365 specific allergens and
allergy panels. In addition, DPC addresses the chemistry and
laboratory automation testing needs of its customers through
partnerships with manufacturers of chemistry systems and reagents. The
combined chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested. DPC
also designs and manufactures automated laboratory instrumentation,
which provides fast, accurate results while reducing labor and reagent
costs. DPC sells its products to hospitals, clinics and laboratories
in more than 100 countries. *Additional Company information can be
found on DPC's website at www.dpcweb.com.

   Except for the historical information contained herein, this press
release contains forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially.
These factors include the effects of governmental or other actions
relating to the FDA's decision that its Application Integrity Policy
should be applied to the Company or relating to the Company's Chinese
affiliate; the rate of customer demand for the Company's products; the
Company's ability to successfully market new and existing products;
its dependence on certain suppliers; domestic and foreign government
regulation; its ability to keep abreast of technological innovations
and to translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC reports
and filings.